Sanofi Pasteur Inc.
50 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
4
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 4 to 30, 2027 · next Jan 4
- 1 fee due Aug 27, 2027The maintenance fee for Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition (US 11,911,452) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Sep 3, 2027The maintenance fee for Multimerization of Recombinant Protein by Fusion to a Sequence from Lamprey (US 10,577,398) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Methods of Cultivating Bordetella Species (US 11,970,690) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Nov 5 US 8,067,565 Dengue Serotype 1 Attenuated Strain · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,067,566 | Dengue serotype 2 attenuated strain In force · USPTO record | In force | USPTO record | |
| US 8,795,688 | Dengue serotype 2 attenuated strain In force · USPTO record | In force | USPTO record | |
| US 7,641,907 | Dengue Serotype 1 Attenuated Strain In force · High confidence | In force | High confidence | |
| US 7,641,908 | Dengue Serotype 2 Attenuated Strain In force · High confidence | In force | High confidence | |
| US 9,019,496 | Method for Estimating the Amount of Entities Deposited on Microparticles in Suspension in a Solution, Associated Device and Use of Said Device In force · High confidence | In force | High confidence | |
| US 9,938,055 | Method of Storing a Vaccine Containing an Aluminum Adjuvant In force · High confidence | In force | High confidence | |
| US 9,365,832 | Purification of Herpes Virus In force · High confidence | In force | High confidence | |
| US 9,358,294 | Method for Formulating a Vaccine Containing at Least Two Antigens Capable of Adsorbing onto Aluminium Oxyhydroxide In force · High confidence | In force | High confidence | |
| US 10,363,304 | Purification of Herpes Virus In force · High confidence | In force | High confidence | |
| US 11,224,650 | Purification of Herpes Virus In force · High confidence | In force | High confidence |
Also on record, not counted in the 37: 50 patents in force now held by others · 93 lapsed for an unpaid fee · 37 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
30 pending · 44 abandoned · 6 no status recorded
Showing 1 to 10 of 80, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/235,094 | Systems and Methods for Designing Vaccines | Jun 11, 2025 | Pending |
| 19/213,013 | Methods for Determining Adjuvanted Protein Concentration and Percent Adsorption Using Intrinsic Fluorescence | May 20, 2025 | Pending |
| 19/196,288 | Respiratory Syncytial Virus Rna Vaccination | May 1, 2025 | Pending |
| 19/046,019 | Compositions for Use in Treatment of Chlamydia | Feb 5, 2025 | Pending |
| 19/022,412 | Neisseria Meningitidis Vaccine | Jan 15, 2025 | Pending |
| 19/020,003 | Human Cytomegalovirus Immunogenic Composition | Jan 14, 2025 | Pending |
| 18/978,229 | Compositions and Methods for Circular Rna Affinity Purification | Dec 12, 2024 | Pending |
| 18/899,212 | Primers and Probes for Detecting Mycobacteria | Sep 27, 2024 | Pending |
| 18/746,742 | Meningococcal B Recombinant Vaccine | Jun 18, 2024 | Pending |
| 18/671,660 | Human Metapneumovirus Viral Vector-Based Vaccines | May 22, 2024 | Pending |
10 of 80 applications shown.
Pro members see all 80 published applications.